


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~Compounds of the~~ A compound of formula I



in which

R^1 and R^2 are each, independently of one another, H, OH, OR^8 , $-SR^8$, $-SOR^8$, $-SO_2R^8$ or Hal,

R^1 and R^2 together are alternatively $-OCH_2O-$ or $-OCH_2CH_2O-$,

R^3 is H, $A''R^9$, $COA''R^9$, $COOA''R^9$, $CONH_2$, $CONHA''R^9$, $CON(A''R^9)(A'''R^9)$, NH_2 , $NHA''R^9$, $N(A''R^9)(A'''R^9)$, $NCOA''R^9$ or $NCOOA''R^9$,

R^4 is H, $A''R^9$, $COA''R^9$, $COOA''R^9$, $CONH_2$, $CONHA''R^9$ or $CON(A''R^9)(A'''R^9)$,

B is an aromatic isocyclic or heterocyclic radical, which may be unsubstituted or monosubstituted, disubstituted or trisubstituted by R^5 , R^6 and/or R^7 ,


X is alkylene having 1-10 carbon atoms or alkenylene having 2-8 carbon atoms, in which one, two or three CH_2 groups may be replaced by O, S, SO, SO_2 , NH or $NA''R^9$,

1-7 H atoms may be replaced by F and/or Cl,

and/or 1 or 2 H atoms may be replaced by R^{11} and/or R^{12} ,

R^5 , R^6

and R^7 are each, independently of one another, H, $A''R^9$, OH, $OA''R^9$, NH_2 , $NHA''R^9$, $N(A''R^9)(A'''R^9)$, $NHCOA''R^9$, $NHCOOA''R^9$, $NHCONH_2$, $NHCONHA''R^9$, $NHCON(A''R^9)(A'''R^9)$, Hal, $COOH$, $COOA''R^9$, $CONH_2$, $CONHA''R^9$, $CON(A''R^9)(A'''R^9)$,



R^8 is A, cycloalkyl having 3-7 carbon atoms or alkylencycloalkyl having 4-8 carbon atoms,

R^9 is H, COOH, COOA, CONH₂, CONHA, CONAA', NH₂, NHA, NAA', NCOA, NCOOA, OH, OA, (CH₂)_n-aryl or (CH₂)_nHet,

R^{10} is alkyl having 1-10 carbon atoms, cycloalkyl having 3-7 carbon atoms, alkylencycloalkyl having 4-8 carbon atoms or alkenyl having 2-8 carbon atoms,

in which one, two or three CH₂ groups may be replaced by O, S, SO, SO₂, NH, NMe, NEt and/or by -CH=CH- groups,

1-7 H atoms may be replaced by F and/or Cl,

and/or 1 H atom may be replaced by R^9 ,

R^{11} is H, A, COOA" R^9 , CONH₂, CONHA" R^9 , CON(A" R^9)(A''' R^9), NH₂, NHA" R^9 , N(A" R^9)(A''' R^9), NCOA" R^9 , NCOOA" R^9 , OH or OA" R^9 ,

R^{12} is H, A, COOA" R^9 , CONH₂, CONHA" R^9 or CON(A" R^9)(A''' R^9),

Y is alkylene having 1-10 carbon atoms or alkenylene having 2-8 carbon atoms,

in which one, two or three CH₂ groups may be replaced by O, S, SO, SO₂, NH or NR¹⁰ and/or

1-7 H atoms may be replaced by F and/or Cl,

A and A' are each, independently of one another, alkyl having 1-10 carbon atoms or alkenyl having 2-8 carbon atoms,

in which one, two or three CH₂ groups may be replaced by O,

S, SO, SO₂, NH or NR¹⁰ and/or
1-7 H atoms may be replaced by F and/or Cl,
or
aryl or Het,

A and A' together are alternatively an alkylene chain having 2-7 carbon atoms, in which one, two or three CH₂ groups may be replaced by O, S, SO, SO₂, NH, NR¹⁰, NCOR¹⁰ or NCOOR¹⁰,

A" and A''' are each, independently of one another, absent, alkylene having 1-10 carbon atoms, alkenylene having 2-8 carbon atoms or cycloalkylene having 3-7 carbon atoms, in which one, two or three CH₂ groups may be replaced by O, S, SO, SO₂, NH or NR¹⁰ and/or 1-7 H atoms may be replaced by F and/or Cl,

A" and A''' together are alternatively an alkylene chain having 2-7 carbon atoms, in which one, two or three CH₂ groups may be replaced by O, S, SO, SO₂, NH, NR¹⁰, NCOR¹⁰ or NCOOR¹⁰,

aryl is phenyl, naphthyl, fluorenyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, R¹⁴, OR¹³, N(R¹³)₂, NO₂, CN, COOR¹³, CON(R¹³)₂, NR¹³COR¹³, NR¹³CON(R¹³)₂, NR¹³SO₂A, COR¹³, SO₂N(R¹³)₂ or S(O)_mR¹⁴,

R¹³ is H or alkyl having 1-6 carbon atoms,

R¹⁴ is alkyl having 1-6 carbon atoms,

Het is a monocyclic or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 or 2 N, O and/or S atoms, which may be unsubstituted or monosubstituted or disubstituted by carbonyl oxygen, Hal, R¹⁴, OR¹³, N(R¹³)₂, NO₂, CN, COOR¹³, CON(R¹³)₂, NR¹³COR¹³, NR¹³CON(R¹³)₂, NR¹³SO₂R¹⁴, COR¹³, SO₂NR¹³ and/or S(O)_mR¹⁴,

Hal is F, Cl, Br or I,

m is 0, 1 or 2, and

n is 0, 1, 2, 3 or 4,

~~and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, prodrug, solvate or a stereoisomer thereof.

2. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, in which R^1 and R^2 are each, independently of one another, H, methoxy, ethoxy, benzyloxy, propoxy, isopropoxy, difluoromethoxy, F, Cl, cyclopentyloxy, cyclohexyloxy or cycloheptyloxy, ~~and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, prodrug, solvate or a stereoisomer thereof.
3. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, in which R^1 and R^2 are each, independently of one another, methoxy, ethoxy, propoxy, isopropoxy, cyclopentyloxy or F, ~~and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, prodrug, solvate or a stereoisomer thereof.
4. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, in which R^1 is 4-methoxy, and R^2 is 3-ethoxy, ~~and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, prodrug, solvate or a stereoisomer thereof.
5. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, in which R^4 is H, ~~and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, prodrug, solvate or a stereoisomer thereof.
6. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, in which R^3 is H, $\text{COO}(\text{CH}_2)_n\text{-aryl}$, $\text{COA}''\text{H}$, $\text{COOA}''\text{H}$, $\text{A}''\text{NAA}'$, $\text{A}''\text{-aryl}$ or $\text{A}''\text{Het}$, ~~and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, prodrug, solvate or a stereoisomer thereof.
7. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, in which

X is methylene, ethylene, propylene or butylene,
~~and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, prodrug, solvate or a stereoisomer thereof.

8. (Currently Amended) ~~Compounds~~ A compound according to Claim 1,
in which

B is phenyl, pyridyl, pyridyl N-oxide, thienyl, furyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, isoxazoliny, oxazoliny, thiazoliny, pyrazoliny, imidazoliny, naphthyl, quinoliny, isoquinoliny, cinnoliny, phthalazinyl, quinazoliny or quinoxaliny, each of which is unsubstituted or may be monosubstituted, disubstituted or trisubstituted by OH, OA, NH₂, NAA', O-alkylene-NAA' or O-alkylene-OH,

~~and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, prodrug, solvate or a stereoisomer thereof.

9. (Currently Amended) ~~Compounds~~ A compound according to Claim 1,
in which

B is phenyl which is unsubstituted or monosubstituted by OR¹³, N(R¹³)₂, O-alkylene-N(R¹³)₂ or O-alkylene-OH, or unsubstituted pyridyl,

~~and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, prodrug, solvate or a stereoisomer thereof.

10. (Currently Amended) ~~Compounds~~ A compound according to Claim 1,
in which

R¹ and R² are each, independently of one another, H, methoxy, ethoxy, benzyloxy, propoxy, isopropoxy, difluoromethoxy, F, Cl, cyclopentyloxy, cyclohexyloxy or cycloheptyloxy,

R¹ and R² together are alternatively -OCH₂O- or -OCH₂CH₂O-,

R³ is H, A''R⁹, COA''R⁹, COOA''R⁹, CONH₂, CONHA''R⁹, CON(A''R⁹)(A'''R⁹), NH₂, NHA''R⁹, N(A''R⁹)(A'''R⁹), NCOA''R⁹ or NCOOA''R⁹,

R⁴ is H,

X is methylene, ethylene, propylene or butylene,

A'' and A''' are each, independently of one another, absent or alkylene having 1, 2, 3 or

4 carbon atoms, and
 R^9 is H, $(CH_2)_n$ -aryl or $(CH_2)_n$ Het,
~~and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, prodrug, solvate or a stereoisomer thereof.

11. (Currently Amended) ~~Compounds~~ A compound according to Claim 1,
 in which

R^1 and R^2 are each, independently of one another, H, methoxy, ethoxy, benzyloxy, propoxy, isopropoxy, difluoromethoxy, F, Cl, cyclopentyloxy, cyclohexyloxy or cycloheptyloxy,
 R^1 and R^2 together are alternatively $-OCH_2O-$ or $-OCH_2CH_2O-$,
 R^3 is H, $A''R^9$, $COA''R^9$, $COOA''R^9$, $CONH_2$, $CONHA''R^9$, $CON(A''R^9)(A'''R^9)$, NH_2 , $NHA''R^9$, $N(A''R^9)(A'''R^9)$, $NCOA''R^9$ or $NCOOA''R^9$,
 R^4 is H,
 X is methylene, ethylene, propylene or butylene,
 A'' and A''' are each, independently of one another, absent or alkylene having 1, 2, 3 or 4 carbon atoms,
 R^9 is H, $(CH_2)_n$ -aryl or $(CH_2)_n$ Het,
 aryl is phenyl, naphthyl, fluorenyl or biphenyl, each of which is unsubstituted or monosubstituted by OR^{13} ,
 R^{13} is H or alkyl having 1-6 carbon atoms,
 Het is pyridyl, pyridyl N-oxide, thienyl, furyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, isoxazolinyl, oxazolinyl, thiazolinyl, pyrazolinyl, imidazolinyl, naphthyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl or quinoxalinyl, and
 B is phenyl which is unsubstituted or monosubstituted by OR^{13} , $N(R^{13})_2$, O-alkylene- $N(R^{13})_2$ or O-alkylene-OH, or unsubstituted pyridyl,
~~and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, prodrug, solvate or a stereoisomer thereof.

12. (Currently Amended) ~~Compounds~~ A compound according to Claim 1,
 in which

R^1 and R^2 are each, independently of one another, methoxy, ethoxy, propoxy or

	isopropoxy,
R ³	is H, fluorenylmethyloxycarbonyl, acetyl, tert-butyloxycarbonyl, benzyloxycarbonyl, N,N-dimethylaminoethyl, benzyl or pyridylmethyl,
R ⁴	is H,
X	is methylene, ethylene, propylene or butylene,
R ¹³	is H or alkyl having 1-6 carbon atoms,
Het	is pyridyl, <u>and</u>
B	is phenyl which is unsubstituted or monosubstituted by OR ¹³ , N(R ¹³) ₂ , O-alkylene-N(R ¹³) ₂ or O-alkylene-OH, or unsubstituted pyridyl;

~~and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, prodrug, solvate or a stereoisomer thereof.

13. ~~(Original) Compounds of the formula I~~ A compound according to Claim 1, ~~which is from the group consisting of~~


- a) benzyl {1-(1S)-(4-tert-butoxybenzyl)-2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl} carbamate,
- b) benzyl {2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-1-(1S)-(4-hydroxybenzyl)-2-oxoethyl} carbamate,
- c) 2-(2S)-amino-1-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-3-[4-(2-hydroxyethoxy)phenyl]propan-1-one,
- d) 3-[4-(2-dimethylaminoethoxy)phenyl]-2-(2S)-(2-dimethylaminoethylamino)-1-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]propan-1-one,
- e) 2-(2S)-amino-3-[4-(2-dimethylaminoethoxy)phenyl]-1-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]propan-1-one,
- f) 9H-fluoren-9-ylmethyl {1-(1S)-(4-tert-butoxybenzyl)-2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl} carbamate,
- g) 2-(2S)-amino-3-(4-tert-butoxyphenyl)-1-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]propan-1-one,
- h) 2-(2S)-amino-1-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-3-(4-hydroxyphenyl)propan-1-one,
- i) 2-(2S)-benzylamino-1-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-3-(4-hydroxyphenyl)propan-1-one,
- j) 1-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-3-(4-

- hydroxyphenyl)-2-(2S)-[(pyridin-4-ylmethyl)amino]propan-1-one,
- k) tert-butyl {1-(1R)-(4-methoxybenzyl)-2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl} carbamate,
- l) tert-butyl {1-(1S)-(4-methoxybenzyl)-2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl} carbamate,
- m) N-{1-(1S)-(4-tert-butoxybenzyl)-2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl} acetamide,
- n) N-[2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-1-(1S)-(4-hydroxybenzyl)-2-oxoethyl]acetamide,
- o) tert-butyl {2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxo-1-(1R)-(pyridin-3-ylmethyl)ethyl} carbamate,
- p) 2-(2R)-amino-1-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-3-pyridin-3-ylpropan-1-one,
- q) tert-butyl {2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxo-1-(1R)-(pyridin-4-ylmethyl)ethyl} carbamate, or
- r) 2-(2R)-amino-1-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-3-pyridin-4-ylpropan-1-one,

and ~~or~~ a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios acceptable salt, prodrug, solvate or a stereoisomer thereof.

14. (Currently Amended) ~~Compounds of the formula I according to Claim 1 as A~~
method for inhibiting phosphodiesterase IV inhibitors comprising administering to a patient in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof.


15. (Currently Amended) ~~Process for the preparation of compounds of the formula I and salts and solvates thereof, characterised in that A process for preparing a compound of claim 1 or a salt or solvate thereof, comprising~~
a) reacting a compound of the formula II



in which

R¹ and R² are as defined in Claim 1,

~~is reacted~~ with a compound of ~~the~~ formula III



in which

L is Cl, Br, I or a free or reactively functionally modified OH group,

and R³, R⁴, X and B are as defined in Claim 1,

with the proviso that any further OH and/or amino group present is protected,

and subsequently, ~~if desired~~ optionally, a protecting group is removed,

or

b) one or more radicals R¹, R², R³, R⁴ and/or B in a compound of the formula I are converted into one or more other radicals R¹, R², R³, R⁴ and/or B by

- i) cleaving an ether or ester,
- ii) alkylating or acylating an OH function,
- iii) reductively alkylating an amino group,

and/or ~~in that~~ a basic compound of ~~the~~ formula I is converted into one of its salts by treatment with an acid.

16. (Currently Amended) ~~Medicaments~~ A pharmaceutical composition comprising at least one compound of ~~the formula I~~ according to Claim 1 ~~and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,~~ and, ~~if desired,~~ or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof and one or more excipients and/or adjuvants.

17. (Currently Amended) A method of ~~using compounds of the formula I according to Claim 1 and/or physiologically acceptable salts or solvates thereof for the preparation of a medicament~~ for the treatment of a patient suffering from a disease or condition mediated by the PDE IV isozyme in its role in regulating the activation and degranulation of human eosinophils, comprising administering to said patient an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof.

18. (Currently Amended) A method ~~as in Claim 17 for the preparation of a medicament~~ for combating an allergic diseases disease, asthma, chronic bronchitis, atopic dermatitis, psoriasis, and other skin diseases disease, inflammatory diseases disease, autoimmune diseases disease, such as, for example, rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes mellitus, or ulcerative colitis, osteoporosis, transplant rejection reactions, cachexia, tumour growth or tumour metastases, sepsis, memory disorders, atherosclerosis and or AIDS, comprising administering to a patient in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof.

19. (Currently Amended) A method ~~as in Claim 17 for the preparation of a medicament~~ for the treatment or prevention of ~~one or more of the diseases, pathological disorders and conditions from the following group:~~

~~asthma, of whatever type, etiology or pathogenesis, or asthma selected from the group consisting of atopic asthma, non-atopic asthma, allergic asthma, atopic, IgE-mediated asthma, bronchial asthma, essential asthma, true asthma, intrinsic asthma caused by pathophysiological disturbances, extrinsic asthma caused by environmental factors, essential asthma of unknown or inapparent cause, non-atopic asthma, bronchitic asthma, emphysematous asthma, exercise-induced asthma, occupational asthma, infective asthma caused by bacterial, fungal, protozoal or viral infection, non-allergic asthma, incipient asthma, or wheezy infant syndrome;~~

~~chronic or acute bronchoconstriction, chronic bronchitis, small airway obstruction and or emphysema;~~

~~obstructive or inflammatory airway disease, of whatever type, etiology or pathogenesis, or an obstructive or inflammatory airway disease selected from the group~~

~~consisting of asthma;~~ pneumoconiosis, chronic eosinophilic pneumonia; chronic obstructive pulmonary disease (COPD), COPD including chronic bronchitis, pulmonary emphysema or dyspnoea associated therewith, COPD that is characterised by irreversible, progressive airway obstruction, acute respiratory distress syndrome (ARDS), and or exacerbation of airway hypersensitivity consequent to ~~either~~ medicament therapy;

~~pneumoconiosis, of whatever type, etiology or pathogenesis, or pneumoconiosis selected from the group consisting of~~ aluminosis, anthracosis (asthma), asbestosis, chalicosis, ptilosis caused by inhaling the dust from ostrich feathers, siderosis caused by the inhalation of iron particles, silicosis, byssinosis or cotton-dust pneumoconiosis and or talc pneumoconiosis;

~~bronchitis, of whatever type, etiology or pathogenesis, or bronchitis selected from the group consisting of~~ acute bronchitis, acute laryngotracheal bronchitis, arachidic bronchitis, catarrhal bronchitis, croupus bronchitis, dry bronchitis, infectious asthmatic bronchitis, productive bronchitis, staphylococcal or streptococcal bronchitis; and or vesicular bronchitis;

~~bronchiectasis, of whatever type, etiology or pathogenesis, or bronchiectasis selected from the group consisting of~~ cylindric bronchiectasis, sacculated bronchiectasis, fusiform bronchiectasis, capillary bronchiectasis, cystic bronchiectasis, dry bronchiectasis and or follicular bronchiectasis;

seasonal allergic rhinitis, perennial allergic rhinitis, or sinusitis, ~~of whatever type, etiology or pathogenesis, or sinusitis selected from the group consisting of~~ purulent or nonpurulent sinusitis, acute or chronic sinusitis, and or ethmoid, frontal, maxillary, or sphenoid sinusitis;

~~rheumatoid arthritis, of whatever type, etiology or pathogenesis, or rheumatoid arthritis selected from the group consisting of~~ acute arthritis, acute gouty arthritis, primary chronic arthritis, osteoarthritis, infectious arthritis, Lyme arthritis, progressive arthritis, psoriatic arthritis and or spondylarthritis;

gout, and or fever and or pain associated with inflammation;

an eosinophil-related pathological disorder, ~~of whatever type, etiology or pathogenesis, or an eosinophil-related pathological disorder selected from the group consisting of~~ eosinophilia, pulmonary infiltration eosinophilia, Löffler's syndrome, chronic eosinophilic pneumonia, tropical pulmonary eosinophilia, bronchopneumonic aspergillosis, aspergilloma, eosinophilic granuloma, allergic granulomatous angitis or

Churg-Strauss syndrome, polyarteritis nodosa (PAN) ~~and or~~ systemic necrotising vasculitis;

atopic dermatitis, allergic dermatitis, or allergic or atopic eczema;

~~urticaria, of whatever type, etiology or pathogenesis, or urticaria selected from the group consisting of~~ immune-mediated urticaria, complement-mediated urticaria, urticariogenic material-induced urticaria, physical stimulus-induced urticaria, stress-induced urticaria, idiopathic urticaria, acute urticaria, chronic urticaria, angioedema, cholinergic urticaria, cold urticaria in the autosomal dominant form or in the acquired form, contact urticaria, giant urticaria ~~and or~~ papular urticaria;

~~conjunctivitis, of whatever type, etiology or pathogenesis, or conjunctivitis selected from the group consisting of~~ actinic conjunctivitis, acute catarrhal conjunctivitis, acute contagious conjunctivitis, allergic conjunctivitis, atopic conjunctivitis, chronic catarrhal conjunctivitis, purulent conjunctivitis ~~and or~~ vernal conjunctivitis;

~~uveitis, of whatever type, etiology or pathogenesis, or uveitis selected from the group consisting of~~ inflammation of all or part of the uvea, anterior uveitis, iritis, cyclitis, iridocyclitis, granulomatous uveitis, nongranulomatous uveitis, phacoantigenic uveitis, posterior uveitis, choroiditis ~~and or~~ chorioretinitis;

psoriasis;

~~multiple sclerosis, of whatever type, etiology or pathogenesis, or multiple sclerosis selected from the group consisting of~~ primary progressive multiple sclerosis ~~and or~~ relapsing remitting multiple sclerosis;

an autoimmune/inflammatory diseases ~~of whatever type, etiology or pathogenesis, or an autoimmune/inflammatory disease selected from the group consisting of~~ disease, autoimmune haematological disorders, haemolytic anaemia, aplastic anaemia, pure red cell anaemia, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, polychondritis, scleroderma, Wegner's granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Stevens-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel diseases, ulcerative colitis, Crohn's disease, endocrine ophthalmopathy, Basedow's disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, primary biliary cirrhosis, juvenile diabetes or type 1 diabetes mellitus, anterior uveitis, granulomatous or posterior uveitis, keratoconjunctivitis sicca, epidemic keratoconjunctivitis, diffuse interstitial pulmonary fibrosis or interstitial pulmonary fibrosis, pulmonary cirrhosis, cystic fibrosis, psoriatic arthritis, glomerulonephritis with

~~and or~~ without nephrotic syndrome, acute glomerulonephritis, idiopathic nephrotic syndrome, minimal change nephropathy, inflammatory/ hyperproliferative skin diseases, psoriasis, atopic dermatitis, contact dermatitis, allergic contact dermatitis, benign familial pemphigus, pemphigus erythematosus, pemphigus foliaceus ~~and or~~ pemphigus vulgaris;

~~prevention of foreign transplant rejection following organ transplantation;~~

~~inflammatory bowel disease (IBD), of whatever type, etiology or pathogenesis, or inflammatory bowel disease selected from the group consisting of ulcerative colitis (UC), collagenous colitis, colitis polyposa, transmural colitis and or Crohn's disease (CD);~~

~~septic shock, of whatever type, etiology or pathogenesis, or septic shock selected from the group consisting of renal failure, acute renal failure, cachexia, malarial cachexia, hypophysial cachexia, uremic cachexia, cardiac cachexia, cachexia suprarenalis or Addison's disease, cancerous cachexia, and or cachexia as a consequence of infection by the human immunodeficiency virus (HIV);~~

liver damage;

pulmonary hypertension ~~and or~~ hypoxia-induced pulmonary hypertension;

bone loss diseases, primary osteoporosis ~~and or~~ secondary osteoporosis;

~~a pathological disorders disorder of the central nervous system, of whatever type, etiology or pathogenesis, or a pathological disorder of the central nervous system selected from the group consisting of depression, Parkinson's disease, a learning and or memory disorders disorder, tardive dyskinesia, drug dependence, arteriosclerotic dementia, and or dementias that accompany Huntington's chorea, Wilson's disease, paralysis agitans and or thalamic atrophies;~~

~~infections, especially an infection, viral infections or infection; where these the viruses increase the production of TNF- α in their host or where these the viruses are sensitive to up-regulation of TNF- α in their host so that their replication or other vital activities are adversely affected, including viruses selected from the group consisting of or a viral infection from HIV-1, HIV-2 and or HIV-3, cytomegalovirus, CMV, influenza, adenoviruses and or Herpes viruses, including virus, Herpes zoster and or Herpes simplex;~~

~~a yeast and or fungal infections, infection where these the yeasts and fungi are sensitive to up-regulation by TNF- α or elicit TNF- α production in their host, for example fungal meningitis, particularly when administered in conjunction with other medicaments of choice for the treatment of a systemic yeast and or fungal infections, including, but not~~

~~limited to, polymycins, for example~~ infection, an infection from polymycin, polymycin B, imidazoles, for example imidazole, clotrimazole, econazole, miconazole and or ketoconazole, triazoles, for example triazole, fluconazole, and or itranazole, and or amphotericins, for example amphotericin, amphotericin B and or liposomal amphotericin B;

ischaemia-reperfusion damage, autoimmune diabetes, retinal autoimmunity, chronic lymphocytic leukaemia, HIV infections, lupus erythematosus, a kidney and or ureter diseases disease, a pathological urogenital and or gastrointestinal disorders and disorder or a prostate diseases disease comprising administering to a patient in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof.

20. (Currently Amended) A method ~~as in Claim 17 for the preparation of a medicament~~ for the treatment of ~~(1) an inflammatory diseases and conditions, including disease or condition,~~ joint inflammation, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, inflammatory bowel disease, ulcerative colitis, chronic glomerulonephritis, dermatitis ~~and or Crohn's disease;~~ ~~(2) an airway diseases and conditions, including disease or condition,~~ asthma, acute respiratory distress syndrome, chronic pulmonary inflammatory disease, bronchitis, chronic obstructive airway disease ~~and or~~ silicosis; ~~(3) an infectious diseases and conditions, including disease or condition,~~ sepsis, septic shock, endotoxic shock, Gram-negative sepsis, toxic shock syndrome, fever ~~and or~~ myalgia due to bacterial, viral or fungal infections, ~~and or~~ influenza; ~~(4) an immune diseases and conditions, including disease or condition,~~ autoimmune diabetes, systemic lupus erythematosus, GvH reaction, rejection of a foreign transplants transplant, multiple sclerosis, psoriasis ~~and or~~ allergic rhinitis; ~~and (5) other diseases and conditions, including or a bone absorption diseases disease,~~ reperfusion damage, cachexia secondary to infection or malignancy, cachexia secondary to AIDS, human immunodeficiency virus (HIV) infection, or AIDS related complex (ARC), keloid formation, scar tissue formation, type 1 diabetes mellitus, ~~and or~~ leukaemia comprising administering to a patient in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof.


21. (Currently Amended) A method ~~as in Claim 17 for the preparation of a medicament~~ for the treatment of a myocardial diseases disease comprising administering to a patient in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof.

22. (Currently Amended) A method ~~as in Claim 17 for the preparation of a medicament~~ for the treatment of a myocardial diseases, ~~where these~~ disease where the myocardial diseases have disease has an inflammatory and or immunological ~~properties~~ property comprising administering to a patient in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof.

23. (Currently Amended) A method ~~as in Claim 17 for the preparation of a medicament~~ for the treatment of coronary heart disease, reversible or irreversible myocardial ischaemia/reperfusion damage, acute or chronic heart failure ~~and or~~ restenosis, including in-stent restenosis and or stent-in-stent restenosis comprising administering to a patient in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof.

24. (Currently Amended) ~~Combination of~~ A pharmaceutical composition comprising a compound according to Claim 1 ~~together with and~~ one or more members of the following group: of


(a) leukotriene biosynthesis inhibitors~~[[:]~~, a 5-lipoxygenase (5-LO) ~~inhibitors~~ inhibitor, and 5-lipoxygenase activating protein (FLAP) ~~antagonists selected from the group consisting of~~ antagonist, zileuton, ABT-761,



ABT-761


N[C@@H](C#Cc1cc2oc(Oc3ccc(F)cc3)cc2o1)C(=O)ON#CC(=O)N[C@H](C#CC1=CC=CC=C1S1)Cc2ccc(F)cc2

N-(5-substituted) thiophene-2-alkylsulfonamides thiophene-2-alkylsulfonamide, 2,6-di-tert-butylphenol hydrazones, Zeneca




- 17 -


MERCK-2948




SB-210661



L-739,010





L-746,530



MK-591


ZD-2138, SB-210661, the pyridinyl-substituted 2-cyanonaphthalene compound L-739,010, the 2-cyanoquinoline compound L-746,530, the indole and quinoline compounds MK-591, MK-886 and or BAY x 1005;

(b) ~~receptor antagonists for the leukotrienes LTB₄, LTC₄, LTD₄ and or LTE₄, selected from the group consisting of the phenothiazin-3-one compound L-651,392, the amidino compound CGS-25019c,~~



CGS-25019c

the benzoxazoline compound ontazolast, the benzenecarboximideamide compound BHL-284/260, the compounds



BIIL 284/260

zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A) and or BAY x 7195;

- (c) PDE IV inhibitors;
- (d) 5-lipoxygenase (5-LO) inhibitors; 5-lipoxygenase activating protein (FLAP) antagonists;
- (e) dual inhibitors of 5-lipoxygenase (5-LO) and antagonists of platelet activating factor (PAF);
- (f) leukotriene antagonists (LTRAs), ~~including LTB₄, LTC₄, LTD₄ and LTE₄~~ antagonists;
- (g) antihistamine H₁ receptor antagonists, ~~including~~ cetirizine, loratadine, desloratadine, fexofenadine, astemizole, azelastine ~~and~~ or chlorpheniramine;
- (h) gastroprotective H₂ receptor antagonists;
- (i) α_1 - ~~and~~ or α_2 -adrenoreceptor agonist vasoconstrictor sympathomimetic agents administered orally or topically for decongestant use, ~~selected from the group consisting of~~ propylhexedrine, phenylephrine, phenylpropanolamine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride ~~and~~ or ethylnorepinephrine hydrochloride;
- (j) one or more α_1 - ~~and~~ or α_2 -adrenoreceptor agonists as listed above under (i) in combination with one or more inhibitors of 5-lipoxygenase (5-LO) as listed above under (a);
- (k) anticholinergic agents, ~~including~~ ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine ~~and~~ or telenzepine;
- (l) β_1 - to β_4 -adrenoreceptor agonists, ~~selected from the group consisting of~~ metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol ~~and~~ or pirbuterol;

- (m) theophylline ~~and~~ or aminophylline;
- (n) sodium cromoglycate;
- (o) muscarinic receptor (M1, M2 ~~and~~ or M3) antagonists;
- (p) COX-1 inhibitors (NSAIDs) ~~and~~ or nitric oxide NSAIDs;
- (q) the COX-2 selective inhibitor rofecoxib;
- (r) insulin-like growth factor type I (IGF-1) mimetics;
- (s) ciclesonide;
- (t) inhalation glucocorticoids with reduced systemic side effects, ~~selected from the group consisting of~~ prednisone, prednisolone, flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate ~~and~~ or mometasone furoate;
- (u) tryptase inhibitors;
- (v) platelet activating factor (PAF) antagonists;
- (w) monoclonal antibodies against endogenous inflammatory entities;
- ~~(x) — IPL 576;~~
- (y) antitumour necrosis factor (TNF α) agents, ~~selected from the group consisting of~~ etanercept, or infliximab ~~and D2E7;~~
- (z) DMARDs, ~~selected from the group consisting of~~ or leflunomide;
- (aa) TCR peptides;

- (bb) interleukin converting enzyme (ICE) inhibitors;
- (cc) IMPDH inhibitors;
- (dd) adhesion molecule inhibitors, ~~including~~ or VLA-4 antagonists;
- (ee) cathepsins;
- (ff) MAP kinase inhibitors;
- (gg) glucose 6-phosphate dehydrogenase inhibitors;
- (hh) kinin B₁ ~~and~~ or B₂ receptor antagonists;
- (ii) gold in the form of an aurothio group together with various hydrophilic groups;
- (jj) immunosuppressive agents, ~~selected from the group consisting of~~ cyclosporine, azathioprine ~~and~~ or methotrexate;
- (kk) anti-gout agents, ~~selected from the group consisting of~~ or colchicines;
- (ll) xanthine oxidase inhibitors, ~~selected from the group consisting of~~ or allopurinol;
- (mm) uricosuric agents, ~~selected from the group consisting of~~ probenecide, sulfinpyrazone ~~and~~ or benzbromarone;
- (nn) antineoplastic agents, which are antimitotic medicaments, ~~selected from the group consisting of~~ or vinblastine ~~and~~ or vincristine;
- (oo) agents for promoting growth hormone secretion;
- (pp) inhibitors of matrix metalloproteases (MMPs), ~~selected from the group consisting of~~ stromelysins, collagenases, gelatinases, aggrecanase, collagenase-1 (MMP-1),

collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10) ~~and~~ or stromelysin-3 (MMP-11);

(qq) transforming growth factor (TGF β);

(rr) platelet-derived growth factor (PDGF);

(ss) fibroblast growth factor, ~~selected from the group consisting of~~ or basic fibroblast growth factor (bFGF);

(tt) granulocyte macrophage colony stimulating factor (GM-CSF);

(uu) capsaicin;

(vv) tachykinin NK₁ ~~and~~ or NK₃ receptor antagonists, ~~selected from the group consisting of NKP-608C; SB233412 (talnetant) and D-4418;~~

(ww) elastase inhibitors, ~~selected from the group consisting of UT-77 and ZD-0892;~~

~~and~~ or

(xx) adenosine A2a receptor agonists.

25. ~~(Currently Amended) Medicaments comprising at least one compound of the formula I according to Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient~~ A pharmaceutical composition according to claim 16, further comprising a further pharmaceutically active compound.

26. ~~(Currently Amended) Set (kit) consisting of~~ A kit comprising separate packs of
(a) ~~an effective amount of a compound of the formula I according to Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios;~~ or a pharmaceutically acceptable salt, prodrug, solvate or a

stereoisomer thereof,

and

- (b) ~~an effective amount of a further medicament~~ pharmaceutically active ingredient ~~ingredient~~
compound.